Climb Bio, Inc.

NASDAQ:CLYM

Biotechnology

Healthcare
$9.30 +0.17%

+$0.02 today

Market cap
$546.27M
Beta
0.10
P/E (TTM)
-14.7
EPS (TTM)
-$0.77
52W Low $1.17High $12.48

Volume 0.87M

Average 0.88M

CLYM Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Climb Bio, Inc.NASDAQ: CLYM

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$303.45M, compared with -$250.66M a year earlier.

Context

  • Retained earnings amounted to 199.2% of total assets at the end of Q1 FY2026, up 74.3 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -21.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$303.45M-4.7% QoQ
Last fiscal yearDec 2025
-$289.73M-26.0% YoY
Year agoMar 2025
-$250.66M-21.1% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.1%——
1 year-26.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(289.73M) USD
Year-over-year change
-26.0%

Retained Earnings vs competitors

How CLYM compares with its peers on the latest reported figures

  • CLYM's Mar 2026 retained earnings of -$303.45M is the 2nd highest of the 5 companies compared; the peer median is -$407.52M.
  • Its year-over-year change of -21.1% is the highest of 4, against a peer median of -45.6%.
  • Retained earnings amounts to 199.2% of total assets for CLYM, versus a peer median of 209.0%.
CLYM Competitors Peer median
Retained Earnings for CLYM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TRAXFirst Tracks Biotherapeutics IncMar 2026$0 ——0.0%
CLYMClimb Bio, Inc.Mar 2026-$303.45M -21.1%—199.2%
UPBUpstream Bio, Inc.Mar 2026-$374.81M -71.9%—117.8%
ELDNEledon Pharmaceuticals, Inc.Mar 2026-$440.23M -21.6%—300.2%
CABACabaletta Bio, Inc.Mar 2026-$560.47M -45.6%—378.3%
Peer median (excluding CLYM) -$407.52M-45.6%—209.0%

Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents46.92M43.59M93.11M87.23M35.69M
Short-term Investments89.56M79.98M13.69M63.69M65.39M
Net Receivables6.52M6.49M2.46M1.12M0
Inventory00000
Other Current Assets852K3.01M112K256K4.77M
Total Current Assets148.25M134.39M110.26M154.87M105.85M
Property, Plant & Equipment (Net)0471K199K490K793K
Goodwill00000
Intangible Assets00000
Long-term Investments24.92M0061.61M59.57M
Tax Assets00000
Other Non-current Assets70K128K15K215K1.53M
Total Non-current Assets24.99M599K214K62.32M61.89M
Total Assets173.24M134.99M110.47M217.19M167.74M
Account Payables1.4M750K66K705K2.27M
Short-term Debt0000256K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00138K31K2.57M
Total Current Liabilities6.03M6.1M2.83M4.93M6.98M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7K022K00
Total Non-current Liabilities7K180K37K375K285K
Total Liabilities6.04M6.28M2.87M5.31M7.27M
Common Stock3K3K3K7K5K
Retained Earnings(75.62M)(120.86M)(155.98M)(229.88M)(289.73M)
Accumulated OCI(123K)(358K)(2K)23K435K
Other Stockholders Equity00000
Minority Interest00000
Total Equity167.2M128.72M107.6M211.88M160.48M
Total Debt0480K349K532K541K
Net Debt(46.92M)(43.11M)(92.76M)(86.7M)(35.14M)

Climb Bio, Inc.

NASDAQ:CLYM

Intrinsic Alpha fair value

Locked

Current Price

$9.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.